Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comprehensive and long-term surveys of COVID-19 sequelae in Japan, an ambidirectional multicentre cohort study: study protocol.
Nakagawara K, Namkoong H, Terai H, Masaki K, Tanosaki T, Shimamoto K, Lee H, Tanaka H, Okamori S, Kabata H, Chubachi S, Ikemura S, Kamata H, Yasuda H, Kawada I, Ishii M, Ishibashi Y, Harada S, Fujita T, Ito D, Bun S, Tabuchi H, Kanzaki S, Shimizu E, Fukuda K, Yamagami J, Kobayashi K, Hirano T, Inoue T, Kagyo J, Shiomi T, Ohgino K, Sayama K, Otsuka K, Miyao N, Odani T, Oyamada Y, Masuzawa K, Nakayama S, Suzuki Y, Baba R, Nakachi I, Kuwahara N, Ishiguro T, Mashimo S, Minematsu N, Ueda S, Manabe T, Funatsu Y, Koh H, Yoshiyama T, Saito F, Ishioka K, Takahashi S, Nakamura M, Goto A, Harada N, Kusaka Y, Nakano Y, Nishio K, Tateno H, Edahiro R, Takeda Y, Kumanogoh A, Kodama N, Okamoto M, Umeda A, Hagimura K, Sato T, Miyazaki N, Takemura R, Sato Y, Takebayashi T, Nakahara J, Mimura M, Ogawa K, Shimmura S, Negishi K, Tsubota K, Amagai M, Goto R, Ibuka Y, Hasegawa N, Kitagawa Y, Kanai T, Fukunaga K. Nakagawara K, et al. Among authors: kawada i. BMJ Open Respir Res. 2021 Nov;8(1):e001015. doi: 10.1136/bmjresp-2021-001015. BMJ Open Respir Res. 2021. PMID: 34836924 Free PMC article.
The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A. Nakachi I, et al. Among authors: kawada i. Mol Cancer Res. 2010 Aug;8(8):1142-51. doi: 10.1158/1541-7786.MCR-09-0388. Epub 2010 Jul 20. Mol Cancer Res. 2010. PMID: 20647329
A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
Yoda S, Soejima K, Yasuda H, Naoki K, Kawada I, Watanabe H, Nakachi I, Satomi R, Nakayama S, Ikemura S, Terai H, Sato T, Morosawa M, Asano K. Yoda S, et al. Among authors: kawada i. Cancer Chemother Pharmacol. 2011 Mar;67(3):717-22. doi: 10.1007/s00280-010-1539-y. Epub 2010 Dec 9. Cancer Chemother Pharmacol. 2011. PMID: 21152917 Clinical Trial.
A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Soejima K, Naoki K, Ishioka K, Nakamura M, Nakatani M, Kawada I, Watanabe H, Nakachi I, Yasuda H, Satomi R, Nakayama S, Yoda S, Ikemura S, Terai H, Sato T, Ohgino K, Arai D, Tani T, Kuroda A, Nishino M, Betsuyaku T. Soejima K, et al. Among authors: kawada i. Cancer Chemother Pharmacol. 2015 Mar;75(3):513-9. doi: 10.1007/s00280-014-2673-8. Epub 2015 Jan 7. Cancer Chemother Pharmacol. 2015. PMID: 25563719 Clinical Trial.
A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.
Ikemura S, Naoki K, Yasuda H, Kawada I, Yoda S, Terai H, Sato T, Ishioka K, Arai D, Ohgino K, Kamata H, Miyata J, Kabata H, Betsuyaku T, Soejima K. Ikemura S, et al. Among authors: kawada i. Jpn J Clin Oncol. 2015 Apr;45(4):356-61. doi: 10.1093/jjco/hyu226. Epub 2015 Jan 22. Jpn J Clin Oncol. 2015. PMID: 25612761 Clinical Trial.
88 results